The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

Claims

27 · 3 independent · depth 3

27 granted claims

›1.independentA method of making a biologically active chimeric protein comprising:na) transfecting a cell with (i) a first DNA construct comprising a DNA molecule …+12

›2.↳ 1The method of claim 1, wherein the portion of an immunoglobulin constant region in (i) or the portion of an immunoglobulin constant region in (ii) is …d2

›3.↳ 1The method of claim 1, wherein the biologically active molecule is interferon.d2

›4.↳ 1The method of claim 1, wherein the biologically active molecule is a viral fusion inhibitor, a growth factor, or a hormone.d2+1

›5.↳ 1The method of claim 1, wherein the biologically active molecule comprises a clotting factor.d2+3

›8.↳ 1The method of claim 1, wherein the dimers are isolated by chromatography.d2

›9.↳ 1The method of claim 1, wherein the cell is a eukaryotic cell.d2

›10.↳ 1The method of claim 1, wherein the eukaryotic cell is a CHO cell.d2

›21.↳ 1The method of claim 1, wherein the first DNA construct and the second DNA construct are in a vector.d2

›12.independentA method of making a biologically active chimeric protein comprising:na) transfecting a first cell with a first DNA construct comprising a DNA molecul…+11

›13.↳ 12The method of claim 12, wherein the portion of an immunoglobulin constant region in a) or the portion of an immunoglobulin constant region in b) is an…d2

›14.↳ 12The method of claim 12, wherein the biologically active molecule comprises a clotting factor.d2+3

›18.↳ 12The method of claim 12, wherein the dimers are isolated by chromatography.d2

›19.↳ 12The method of claim 12, wherein the first cell or the second cell is a eukaryotic cell.d2+1

›22.↳ 12The method of claim 12, wherein the biologically active molecule is interferon.d2

›23.↳ 12The method of claim 12, wherein, the biologically active molecule is a viral fusion inhibitor, a growth factor, or a hormone.d2+1

›26.independentA method of making a biologically active chimeric protein comprising:na) transfecting a cell with (i) a first DNA construct comprising a DNA molecule …+1

Classifications

23 codes

IPC · International Patent Classification

Section A — Human necessities

A61K39/00

Section C — Chemistry; metallurgy

C12N9/96
C07K14/00
C07K14/56
C07K14/745
C07K14/565
C12N9/64
C07K16/00
C07K14/505
C07K14/555
C12P21/08
C07K1/00
C07K14/475

USPC · US Patent Classification

435/69.7530/391.7435/69.3435/69.6530/387.3435/69.4424/178.1530/387.1424/134.1435/69.51

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

2.1 y

760 days filing → grant

Office actions

after a restriction

Responses

no RCE

Examiner

Louise Humphrey

art unit 1648 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 332 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

2 priority documents

Priority

6 May 2003

earliest claimed

›Priority documents — 2

Type	Document	Date
provisional	US 60469600	6 May 2003
related publication	US 20130171138 A1	4 Jul 2013

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.